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INTRODUCTION 
Decompensated liver disease is most common Medical problem in our Country. 
Commonest causes of development of cirrhosis are alcohol, Hepatitis Virus 
(B&C) and other metabolic causes. Cirrhotic patient will develop various 
complications if not on proper treatment like UGI bleed due to esophageal 
varix, Hypatic encephalopathy, spontaneous bacterial peritonitis, Hepato renal 
syndrome. Coagulopathy and Hepato pulmonary syndrome, Hepatocellular 
caricinoma. 
Study concentrated on parameters of hepto renal dysfunction. Cystation C 
is a early marker of development of hepatorenal syndrome in DCLD patient. 
Cystatin C is nonglycosylated low molecular wt. protein of the cystatin super 
family of cysteine protease inhibitors. Normal range (0.5-1.5mg./ dl) Cystatin C 
levels raised before rise of other renal parameters like creatinine, urea. Serum 
creatinine levels have limitations in cirrhotic patient  usually low levels in 
DCLD pt due to ↓ synthesis & ↓  production due to muscle mass ↓, Drugs, 
presence of high bilirubin. 
Cystatic C independent of muscle mass, age, gender not influenced by 
serum bilirubin & malignancy, cystatin C levels measurement more advantages 
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and early marker for development of renal dysfunction in DCLD patient and 
prevent the development of end stage renal disease.  
AIMS OF THE STUDY 
1.A study on parameters of Hepatorenal Dysfunction in cases of DCLD at a 
Tertiary Care Centre 
2.To study the complication of  DCLD  
PRIMARY OBJECTIVE- Role of cystatin C in Hepatorenal Dysfunction case 
of Cirrhosis. 
SECONDARY OBJECTIVES- 
1.To study the prevalence of causes of DCLD  
2.To study the frequency of  complication of DCLD  
3.To study the advantages of Cystatic over Serum creatinine by using eGFR  
JUSTIFICATION OF STUDY-   
DCLD is major health problem among males in India most commonest 
cause of death in DCLD is HRS. It is very important to study early marker of 
AKI in DCLD patient. Serum creatinine levels have limitations in cirrhotic 
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patient  usually low levels in DCLD pt due to ↓ synthesis & ↓  production due to 
muscle mass ↓, Drugs, presence of high bilirubin. 
REVIEW LITERATURE  
DECOMPENSATED LIVER DISEASE 
Patient with chronic liver disease can present with acute decompensation due to 
various causes.  
The decompensation may take the form of any of the following complications: 
• Esophageal variceal bleeding 
• Ascites 
• Spontaneous bacterial peritonitis 
• Hepatic encephalopathy 
• Hepatorenal syndrome 
• Coagulopathy 
• Hepatocellular carcinoma 
• Hepatopulmonary syndrome 
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CIRRHOSIS 
 Cirrhosis defined as irreversible chronic injury of the hepatic parenchyma 
and include extensive fibrosis in association with formation of regenerative 
nodules. Cirrhosis classified as  
• Micronodular cirrhosis (<3mm) 
• Macronodular cirrhosis (>3mm) 
Causes of cirrhosis: 
Alcoholism (60-70%) 
Chonic viral hepatitis (10%) 
• Hepatitis B 
• Hepatitis C 
Autoimmune hepatitis 
Non alcoholic hepatitis 
Biliary cirrhosis(5-10%) 
• Primary biliary cirrhosis 
• Primary sclerosing cholangitis 
• Autoimmune cholangiopathy 
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Cardiac cirrhosis 
Inherited metabolic live disease 
• Hemochromatosis 
• Wilson’s disease 
• Alpha 1 antitrypsin deficiency 
• Cystic fibrosis 
Cryptogenic cirrhosis 
COMPLICATIONS OF CIRRHOSIS 
1) HEPATO RENAL SYNDROME 
History :  
Freriechs and Flint (1861-63) reported an association between advanced liver 
disease and  a type of renal impairment that is characterized by oliguria, the 
absence of proteinuria, and normal renal histology.  
In 1932, Helvig and Schultz introduced the term ‘a liver and kidney syndrome’. 
Epstein et al demonstrated the importance of splanchnic and systemic 
vasodilation together with renal vasoconstriction as a foundational concept in 
the pathopathology of HRS. 
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DEFINITION  
HRS is a distinct form of functional acute/subacute renal failure characterised 
by severe renal vasoconstriction which develops in decompensated cirrhosis or 
acute liver failure in the absence of an underlying renal pathology. 
 Causes of renal failure in cirrhosis: 
• Large volume paracentesis 
• Shock 
• Sepsis 
• Nephrotoxic drugs 
• Intrinsic renal disease 
• Volume depletion secondary to diuretics 
EPIDEMIOLOGY 
In patients admitted with DCLD ,  
o 18% develops HRS by one year   and  
o 39 % by five years. 
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PATHOPHYSIOLOGY OF HRS: 
 The peripheral arterial vasodilation theory is the most widely accepted 
explanation for the pathophysiology of HRS, which proposes that splanchnic 
vasodilation that occurs as a consequence of portal hypertension with cirrhosis 
is the inciting factor for the development of HRS. Splanchnic vasodilation is 
mediated principally by nitric oxide but also to a lesser extent by other 
vasodilator substances such as carbon monoxide, glucagon, vasodilator 
peptides, and others. 
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PRECIPITATING FACTORS FOR HRS: 
 Gastro intestinal bleed 
 Large volume paracentesis, without albumin 
 Bacterial infection 
 Spontaneous bacterial peritonitis 
 Acute alcoholic hepatitis 
Types of HRS: 
Type 1 : Cirrhosis with rapidly progressive acute renal failure , cr > 2.5 
Type 2 :Cirrhosis with subacute Renal failure, cr > 1.5 
Type 3: Cirrhosis with type 1 or 2 HRS superimposed on chronic kidney 
disease / acute renal injury 
Type 4: Fulminant hepatic failure with HRS 
DIAGNOSTIC CITERIA: 
 HRS is a diagnosis by exclusion. 
Major Criteria 
(i)Chronic or acute liver disease with advanced hepatic failure and portal 
hypertension. 
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(ii)Low GFR as indicated by serum creatinine > 1.5 mg/dL or 24 hr 
creatinine clearance < 40 mL/min. 
(iii)Absence of shock, on-going bacterial infection, and current or recent 
treatment with nephrotoxic drugs and absence of gastrointestinal fluid losses 
(repeated vomiting or intense diarrhoea) or renal fluid losses (weight loss > 
500 g/day for several days in patients with ascites without peripheral edema or 
1000 g/day in patients with peripheral edema. 
(iv)No sustained improvement in renal function (decrease in serum 
creatinine ≤ 1.5 mg/dL or increase in creatinine clearance to ≥ 40 mL/min) 
following diuretic withdrawal and expansion of plasma volume with 1.5 L of 
isotonic saline. 
(v)Proteinuria < 500 mg/dL and no sonographic evidence of obstructive 
uropathy or parenchymal renal disease. 
Minor Criteria 
(i)Urine volume < 500 mL/day. 
(ii)Urinary sodium < 10 mEq/L. 
(iii)Urinary osmolality greater than plasma osmolality. 
(iv)Urine red blood cells < 50 per high power field. 
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(v)Serum sodium < 130 mEq/L. 
TREATMENT: 
General management: 
o Type 1 HRS – Hospitalisation 
o Type 2 HRS – Outpatient 
CVP for assessing fluid status 
Stoppage of diuretics. 
Tense ascites – paracentesis 
• If >5  L fluid removed, then albumin is a good volume expander 
Low salt diet, 
Free water restriction (for hyponatremic cases) 
HRS type 1 and 4 need intensive care 
THERAPEUTIC OPTIONS 
 Pharmological treatment 
 Surgical 
 TIPS 
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 Artificial liver support 
 Liver transplantation 
 LKT 
 
MEDICAL TREATMENT  
Treatment of hepatorenal syndrome. 
Drug Dose 
Terlipressin 
• Bolus: 0.5–2.0 mg intravenously every 4–6 hours, with 
stepwise dose increments if there is no improvement of 
serum creatinine, to a maximum of 12 mg/day or the 
occurrence of complications, in combination with 
albumin. 
• Continuous infusion: 4 mg/day with stepwise dose 
increments if there is no increase in mean arterial blood 
pressure >10 mmHg or improvement in serum 
creatinine level, up to a maximum of 12 mg/day or the 
occurrence of complications, in combination with 
albumin. 
Noradrenaline • Continuous infusion with a starting dose of 0.5 mg/h, 
with stepwise increments if there is no increase in mean 
arterial blood pressure >10 mmHg or improvement of 
serum creatinine level, up to a maximum of 3 mg/h or 
the occurrence of complications, in combination with 
albumin. 
Midodrine plus 
octreotide 
• Oral midodrine 7.5–12.5 mg three times daily to 
increase mean arterial blood pressure >10 mmHg. 
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Drug Dose 
• Octreotide 200 μg subcutaneously three times daily. 
Albumin • 1 g albumin/kg body weight on the first day, followed 
by 200–400 g daily. 
 
Prophylaxis against hepatorenal system. 
• Prompt and adequate treatment of hypovolemic situations 
• Albumin substitution in spontaneous bacterial peritonitis (SBP) 
• Albumin substitution with large-volume paracentesis 
• Antibiotic prophylaxis in patients at increased risk of SBP 
• Withdrawal of β-blockers in patients with cirrhosis with recurrent and 
refractory ascites 
• Withdrawal of nonsteroidal drugs in portal decompensation 
• Nephroprophylaxis in patients with cirrhosis when radiologic studies 
using contrast medium are performed 
Liver transplantation: 
o Treatment of choice for type 1 and 2 HRS. 
o HRS disappears in the first month of transplantation 
13 
 
o Cyclosporine avoided in first few days after transplantation 
o 3 year survival  
- 60% in patients with HRS 
- 70-80% in patients without HRS 
 
Scoring systems used in cirrhosis: 
1.Child-Pugh score: 
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2)Model for End-Stage Liver Disease (MELD) system: 
The MELD score is a prospectively derived system designed to predict 
the prognosis of patients with liver disease and portal hypertension. This score 
is calculated from three noninvasive variables:  
 the prothrombin time expressed as the international 
normalized ratio (INR),  
 the serum bilirubin level, and  
 the serum creatinine concentration. 
MELD = 3.8 [serum bilirubin (mg/dl)] + 11.2[INR] + 9.6 [serum creatinine 
(mg/dL)] + 6.4 
CYSTATIN C (or) CYSTATIN 3: 
• Cystatin C is a non-glycosylated basic protein encoded by the CST3 gene 
on the short arm of chromosome 20. 
• It was first described as ‘gamma-trace’ in 1961 as a trace protein in CSF 
and urine of patients with renal failure 
• Grubb and Lofberg first reported its aminoacid sequence. It was first 
proposed as a measure of GFR by Grubb and coworkers in 1985 
• It is mainly used as a biomarker of kdney function. 
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•  Normal levels in blood are 0.5 to 1.5 mg/dL. Levels vary with increasing 
age. It is found in all tissues and body fluids 
• It is a potent inhibitor of liposomal proteinases and one of the most 
important extracellular inhibitor of cysteine proteases 
• Recently it has been studies for its role in predicting new onset 
cardiovascular disease 
• It also involves roles in brain disorders like amyloid, Alzheimer’s disease 
• GFR is a marker of kidney function, it is most accurately measured by 
injecting compounds such as inulin, radioisotopes, such as Uronium 
EDTA, I125, Tc99 DTPA 
• These techniques are complicated, costly, time consuming and have side 
effects 
• Creatinine is most widely used as a biomarker of kidney function. It is 
inaccurate in mild renal impairment 
• Levels can vary with muscle mass, but not with protein intake 
• Urea levels may change with protein intake 
• Formulas such as Cockroft-Gault formula and MDRD formula try to 
adjust for these variables 
• Cystatin C low molecular weight (13.3 kilo Daltons) and it is removed 
from the blood stream by glomerular filtration in kidney 
• If kidney function and GFR reduces, the blood levels of Cystatin C rises 
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• Cystatin C levels are less dependant on age, sex, race and muscle mass 
compared to creatinine 
• Cystatin C levels have been reported to be altered in patients with cancer, 
thyroid dysfunction and corticosteroid therapy 
• Levels seem to be increased in HIV infection, which may sometimes be 
mistaken as renal failure 
• Cigarette smoking and levels of C-reactive protein influence Cystatin-C 
Other roles: 
• Mutation in the cystatin 3 gene are responsible for a type of cerebral 
amyloid angiopathy a condition predisposing to stroke, ICH, dementia 
• Cystatin C also binds amyloid Beta and reduces its aggregation and 
deposition if it is a potent target in Alzheimer’s. Cystatin C is higher 
in Alzheimer’s disease 
• Role of cystatin C in multiple sclerosis remains controversial 
• Cystatin C levels are decreased in atherosclerotic and aneurismal 
lesion of the aorta 
• Cystatin C has investigated for prognostic marker of several forms of 
cancer 
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CREATININE 
Creatinine is a metabolic product of creatine derived mainly from myocytes and 
dietary meat. The typical daily production rates are 20 to 25 mg/kg/day in men and 15 
to 20 mg/kg/day in women. Persons with high muscle mass will be having high 
creatinine production, compared to those with low muscle mass. The normal range for 
creatinine is reported between 0.4 and 1.5mg/dL. Kidney eliminates creatinine mainly 
by glomerular filtration and, to a lesser extent, by proximal tubular secretion 
.Glomerular filtration rate accounts for more than 90% of creatinine elimination. 
Creatinine is not absorbed or metabolized to any significant amount in kidney. 
Creatinine is clinically more used to track kidney function, as it accumulates when 
renal elimination is compromised. An increase in creatinine suggests a reduction in 
GFR. Likewise, a decrease in creatinine suggests an improvement in GFR. It is 
important to understand that a change in plasma creatinine does not always correlate 
with decline in renal function in a linear fashion (diagram 1) ie A small increase in 
creatinine at a lower creatinine level may signals greater decline in renal function, 
compared to same increase in creatinine when the baseline creatinine levels are high. 
 Creatinine is not a perfect marker due to the variable contribution of tubular secretion 
of creatinine. When the renal function declines, tubular secretion of creatinine 
increases. Because of this, creatinine based estimation of GFR can overestimate renal 
function because of the increasing proportion of creatinine eliminated by tubular 
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secretion in renal failure.  In addition to that, intra-laboratory variation are also present 
for measurement of creatinine. 
 
 
UREA 
Urea elimination by kidney is more complex than that of  creatinine. This is what  
renders blood urea nitrogen as not a useful marker of kidney function .Elevation in 
blood urea nitrogen may be due to many reasons like gastrointestinal bleeding, steroid 
use and parenteral nutrition . Reduction in blood urea nitrogen can be seen in 
malnutrition and liver disease. Blood urea nitrogen will become more informative 
when the ratio of BUN: creatinine exceeds 20:1.It will give clue regarding pre renal 
AKI.  
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CLEARANCE 
Clearance means “quantity of fluid which completely cleared of a marker over a 
definite period of time.” It is commonly expressed in mL per minute. Marker for 
clearance should be biologically inert, freely and completely filtered by the 
glomerulus. It should be neither secreted nor absorbed by tubules. It should not be 
degraded by the kidney. GFR can be calculated from the measurements of the 
markers’ clearance with the help of an ideal marker.   
ie GFR=(U marker × volume of urine/P marker)1440 
U marker  concentration of the marker in the urine. 
Volume of urine is the volume produced over 24 hours(in mL) 
P marker  concentration of the marker in the plasma. 
Value of 1440 has been used to convert the units to mL  per minute.(1440 minutes in 
24 hours). 
The classic gold standard marker for the measurement of creatinine clearance is 
inulin. But, many substances has been superceded inulin such as iothalamate, 
diethylenetriamine, pentaacetic acid, iohexal ethylene diamine tetra acetic acid. These 
substances are very useful in the accurate measurement of GFR. They used to use in 
special circumstances which require more precision than estimates from creatinine 
clearance. 
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CREATININE CLEARANCE 
Creatinine clearance is not an ideal marker due to the contribution from tubular 
secretion. But  it  can be measured easily and can be used clinically to estimate GFR. 
Creatinine clearance can be done through equation based estimations or by 24 hour 
urine collection. Following equations are the most commonly used equations based on 
creatinine to find out the  kidney functions in adults 
1. Cockcroft-gault equation 
2. MDRD formula 
COCKCROFT – GAULT EQUATION 
Estimated creatinine clearance =(140-age)×weight in kg×0.85(if 
female)/72×plasma creatinine. 
This formula originally developed to use in male inpatients .But, later found to be 
useful in other populations too. 
      The main drawbacks of this equation  
1. difficult to measure the actual lean body  weight of the patient 
2. overestimation of true GFR with creatinine clearance with lower levels of 
kidney function.  
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MDRD EQUATION 
Estimated GFR=186×(Scr)-1.154×(age)-0.203*0.742(if female)*1.21(if African 
American) 
The MDRD formula originally found out in established outpatient CKD patients 
using iothalamate renal clearance as reference. MDRD formula correlates good in 
CKD patients with GFR<60mL/min/1.73m2..But  there are certain situations where 
24 hour urine collection is better than MDRD formula. 
1. GFR>60 ml/min/1.73 m2. 
2. Age < 18 and > 70 
3. Extremely body size 
4. Severe malnutrition 
5. Pregnancy 
6. Skeletal muscle disease 
7. Paraplegia or quadriplegia 
8. Vegetarian 
9. Rapid change in renal function 
10.advanced kidney disease 
MDRD formula has been adjusted for African American population but not for 
Hispanics or Asian popoulations. MDRD formula primarily developed in white 
population not having diabetic kidney disease. 
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Both these equations might be less accurate in populations with different ethnicities 
outside the united states. 
OESOPHAGEAL VARICEAL BLEED  
Definition of a variceal bleed 
• Oesophageal varices are dilated oesophageal veins secondary to portal 
hypertension.  
Causes of variceal bleeds  
• Pre-hepatic  
o Portal vein thrombosis / obstruction  
o Increased portal blood flow: fistula  
• Hepatic  
o Cirrhosis  
 90% of cirrhotic patients get varices, 30% bleed 
o Acute hepatitis (esp. alcoholic)  
o Schistosomiasis  
o Congenital hepatic fibrosis  
• Post-hepatic  
o Compression (e.g. from tumour)  
o Budd-Chiari syndrome  
o Constrictive pericarditis (and rarely right-sided heart failure) 
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Management of variceal bleeds  
• Resuscitation  
o ABC  
 Oxygen, blood tests (VBG, FBC, U+Es, LFTs, clotting, X-match)  
 Erect CXR 
 Fluid resuscitation 
 HDU/ITU 
 Monitoring 
• CVP line and catheter  
• Correct anaemia and coagulopathy  
o Transfusion trigger should be 7 (aim 7-9)  
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 Using a trigger of 9 significantly increases mortality at 45 days 
(NEJM 2013).  
• •Terlipressin (glypressin) 2g IV  
o Vasopressin analogue. Reduces portal pressure. Contraindicated in shock and 
peripheral vascular disease  
• Octreotide (a somatostatin analogue)  
• Antibiotics  
o Broad spectrum. IV Tazocin 4.5g. Blood is an excellent culture medium so these 
patients often end up septic without antibiotics. It may also be a subacute bacterial 
infection that has brought the patient into hospital initially. 
• Endoscopy (once stable and not bleeding) 
• Band ligation 
 This is the first choice of treatment 
Sclerotherapy 
 In this therapy the varices are sclerosed 
 Various sclerosants can be used 
 Complications include transient fever, dysphagia, chest pain, 
ulceration and stricture. 
Variceal obturation with glue 
 This involves embolisation of varices with a glue-like substance (N-
butyl-2-cyanoacrylate) 
 Particularly good for gastric or gastro-oesophageal variceal bleeding 
 However, there is a risk of embolisation to the lung, spleen or brain 
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Transjugular intrahepatic portosystemic shunt (TIPSS) 
o Where bleeding is not controlled by endoscopy 
o Patient needs to be transferred to a specialist liver unit 
o Hepatic vein is cannulated percutaneously via the internal jugular vein using 
a needle under ultrasound guidance and a tract is created through the liver from 
the hepatic to the portal vein reducing portal pressure. 
o High success rate but encephalopathy found in 25% cases (as portal blood 
diverted from the liver) and shunt occludes within 1 year in up to 50% cases 
• Prevention of variceal bleeding 
1.  Beta blockers 
 These lower portal blood pressure and risk of further bleeding by 
reducing portal blood flow. 
2. Nitrates 
 Just for secondary prophylaxis. 
 Nitrates can also be used in the acute variceal haemorrhage with 
vasopressin and terlipressin. 
3. Endoscopic screening 
 All patients with newly-diagnosed cirrhosis should have screening 
endoscopy, looking for oesophageal varices. In the long-term, repeated 
endoscopic screening is usually required, e.g. 2 to 3-yearly in cases of 
small varices. 
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HEPATIC ENCEPHALOPATHY 
Common precipitants of hepatic encepalopathy 
• Renal failure 
• Gastrointestinal bleeding 
• Infection 
• Constipation 
• Sedative drugs e.g. opiates, benzodiazepines, antidepressants and antipsychotic 
drugs 
• Diuretics 
• High protein intake 
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Presentation of hepatic encepalopathy 
• Mild 
o Impairment of attention and decision-making, and may have impaired fitness 
to drive. These patients usually have normal function on standard mental state 
testing but abnormal psychometric testing. 
 
• Moderate 
1. Confusion 
2. Asterixis 
3. Fetor hepaticus 
4. Hypothermia 
5. Hyperventilation 
 
• Severe  
Coma with or without response to painful stimuli  
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Investigations in hepatic encepalopathy 
• Full septic screen 
• Ascitic tap to check for SBP 
• DRE to check for faecal impaction 
• Ammonia levels are raised and can help with diagnosis. The sample needs to be 
collected and then stored on ice and sent directly to the laboratory. 
• EEG 
o High-amplitude low-frequency waves and triphasic waves - not specific for 
hepatic encephalopathy. 
• MRI/CT can help to exclude other causes of altered mental function such as 
intracranial lesions 
• Visual evoked responses show classic patterns associated with hepatic 
encephalopathy. 
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Management of hepatic encepalopathy 
• Lactulose or enemas 
- To clear the nitrogen load 
• Antibiotics 
- To stop nitrogen breakdown 
 Metronidazole 
- Prophylactic antibiotics 
 Rifaximin 550mg twice daily is licensed for prevention of hepatic 
encephalopathy 
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Spontaneous bacterial peritonitis (SBP) 
Epidemiology of SBP: 
• 10-30% of patients with ascites and has mortality rate of 20%. 
• Organisms are usually E. coli, streptococci and enterococci. 
Symptoms of spontaneous bacterial peritonitis (SBP) 
• Generalised abdominal pain 
• Hepatic encephalopathy, renal impairment or peripheral leucocytosis without 
any obvious precipitating factor. 
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Investigations in suspected SBP 
• Diagnostic paracentesis 
- Mandatory in all patients with cirrhosis requiring hospital admission 
- Ascitic fluid contains >250 cells/mm. 
Treatment spontaneous bacterial peritonitis (SBP) 
• Prompt broad spectrum iv antibiotics 
- e.g. Tazocin 4.5g three times daily 
- Treat as soon as ascitic tap has been sent if high index for suspicion 
• If fluid resuscitation needed for septic shock then try to avoid 
colloid/crystalloid and use plasma expander such as human albumin solution 
instead. 
• Good evidence for prophylactic antibiotics after one episode of SBP 
- E.g. Ciprofloxacin 250mg twice daily 
32 
 
SUPPORTING  LITERATURES 
Several studies have been published regarding advantage of Cystatin C over 
Serum creatinine.  
1. Study was conducted in Department of Medicine and Nephrology, INHS 
Asvini, Colaba, Mumbai, Maharastra, India during from September 2008 to 
September 2010 at a tertiary care hospital. The study group consisted of 200 
healthy subjects and 130 patients of AKI. After obtaining an informed consent, 
a screening questionnaire was filled to collect information such as age, gender, 
height, weight, comorbidities, personal history, drug history, presenting 
complaints, and laboratory investigations. A detailed physical examination was 
carried out. 
The serum cystatin C and serum creatinine values were measured 
simultaneously and analyzed. In the AKI study group, they were taken within 
24 hours of onset of injury. The “RIFLE” criteria were used for defining the 
AKI, and the stages “risk” and “injury” constituted the “early AKI.” 
GFR was estimated using the Cockcroft-Gault formula for creatinine clearance 
and Larsson formula for cystatin C-based GFR. 
Larsson formula: eGFR = 77.24 × cystatin C−1.2623 
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The gold standard for measuring GFR viz. inulin clearance, urinary clearance of 
exogenous radioactive markers (125I-iothalamate and 99mTc-DTPA (diethylene-
triamine -pentaacetate)), was not used in this study due to practical limitations. 
Statistical analysis was performed using appropriate statistical tests and P value 
less than 0.05 was considered significant. 
Demographic and biochemical characteristics of study population 
Serum cystatin C had lower standard deviation (1.1) and serum creatinine had 
higher standard deviation (1.8) in AKI indicating lesser variability of serum 
cystatin C. 
The variation of serum creatinine was significantly greater than that of serum 
cystatin C in both groups. The standard deviation of serum creatinine (0.23) is 
double that of serum cystatin C (0.12) in the healthy group, which indicates a 
wide fluctuation in serum creatinine compared to serum cystatin C in healthy 
population too. 
Although the correlation between serum creatinine and serum cystatin C was 
significant in both groups, a high strength of correlation was observed in the 
AKI group. This implies that small changes in serum creatinine are best 
reflected by a proportionate rise in serum cystatin C in AKI, especially at lower 
values. 
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Correlation between serum creatinine and serum cystatin C 
In our study, it was found that in the AKI group majority (56.2%) had normal 
creatinine values (0.9–1.4 mg/dl). This subset was in “creatinine blind” range 
where serum creatinine values are normal with elevated cystatin C levels. All 
130 patients with AKI had deranged cystatin C levels. This confirms the finding 
that serum cystatin C is elevated much before serum creatinine levels start rising 
and does not suffer from the disadvantage of creatinine blind area. In this way it 
helps for early detection of kidney injury. 
2. A total of 192 patients were enrolled in our cohort with cirrhosis and AKI. Of 
these, 106 had at least 2 blood samples collected and were included in this 
study. Samples were not collected in the remaining 86 patients either due to 
failure to consent to blood collection or initiation of dialysis prior to obtaining 
consent. Baseline demographic, clinical, and laboratory characteristics for the 
entirety of study participants and the four groups designated by trends in 
creatinine and cystatin C are shown in . There were no significant differences in 
any demographic variables or in those relating to the patients' liver disease 
between those patients who did and did not have serum samples collected. The 
mean patient age was 56.3 and 66% were male. Thirty-seven (35%) patients met 
the primary composite endpoint during their hospitalization. Of these, 28 
patients died and 22 required dialysis, with 13 of these experiencing both 
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dialysis and death. On sensitivity analysis, there was no difference in death, 
28/106 (26%) versus 22/86 (26%), or the composite of death or dialysis, 37/106 
(35%) versus 30/86 (35%), between those patients with and without blood 
samples obtained. The majority of patients had advanced cirrhosis evidenced by 
previously suffered complications including ascites, 76%, hepatic 
encephalopathy, 63%, variceal bleeding, 23%, and SBP, 12%. Reasons for 
admission were similar between the four groups. The median Child-Pugh score 
was 10 and MELD 26.4 at the time of enrollment. There was no difference in 
Child-Pugh and MELD scores across groups nor were serum sodium levels or 
the presence of hyponatremia at enrollment significantly different. 
The Serum Cr and CysC levels were 1.04 ± 0.1 and 1.8 ± 0.8 mg/L, 
respectively. HRS developed in 18 patients during the follow-up period 
(6 months). Type 1 HRS was found in 5 patients and type 2 HRS was found in 
13 patients with no significant difference between both types regarding 
baseline characteristics. Age (p < 0.001), albumin (p < 0.001), sodium 
(p < 0.005), cystatin C (p < 0.001), and e-GFRMDRD (estimated glomerular 
filtration rate—modification of the diet in renal disease) (p < 0.007) were 
significant dependent predictive factors for the development of HRS. The 
CysC level was the most independent predictive factor for HRS (OR, 2.1; 95% 
CI, 0.75–0.97; p < 0.002). Eighteen patients died during the follow-up period. 
Age (p < 0.001), INR (p < 0.001), e-GFRMDRD (p < 0.03), sodium (p < 0.01), 
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MELD score (p < 0.05), albumin (p < 0.001), and CysC (p < 0.001) levels 
were significant dependent factors for predicting mortality. CysC (OR, 
5.3; p < 0.006) level and INR (OR, 1.01; p < 0.006) were the most independent 
factors for predicting mortality. 
Serum cystatin C had lower standard deviation (1.1) and serum creatinine had 
higher standard deviation (1.8) in AKI indicating lesser variability of serum 
cystatin C. 
The variation of serum creatinine was significantly greater than that of serum 
cystatin C in both groups. The standard deviation of serum creatinine (0.23) is 
double that of serum cystatin C (0.12) in the healthy group, which indicates a 
wide fluctuation in serum creatinine compared to serum cystatin C in healthy 
population too. 
Although the correlation between serum creatinine and serum cystatin C was 
significant in both groups, a high strength of correlation was observed in the 
AKI group. This implies that small changes in serum creatinine are best 
reflected by a proportionate rise in serum cystatin C in AKI, especially at lower 
values. 
In our study, it was found that in the AKI group majority (56.2%) had normal 
creatinine values (0.9–1.4 mg/dl). This subset was in “creatinine blind” range 
where serum creatinine values are normal with elevated cystatin C levels. All 
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130 patients with AKI had deranged cystatin C levels. This confirms the finding 
that serum cystatin C is elevated much before serum creatinine levels start rising 
and does not suffer from the disadvantage of creatinine blind area. In this way it 
helps for early detection of kidney injury. 
Multiple logistic regression applied to GFR calculated by Cockroft-Gault using 
serum creatinine and GFR-calculated serum cystatin C in AKI group gave a 
correlation coefficient (R) of 0.822. This showed a good positive correlation 
between creatinine-based GFR and cystatin C-based GFR. Correlation 
coefficient of creatinine-based GFR is -0.00213 and that of cystatin C-based 
GFR is -0.00673. Cystatin C-based GFR resulted in more negative correlation 
compared to creatinine-based GFR in the AKI group. It means cystatin C-based 
GFR reflects a decline in GFR with worsening AKI in a much better way 
compared to creatinine-based GFR. The P value was significant (P < 0.01) for 
both cystatin C- and creatinine-based GFR. 
Thus in the AKI group, cystatin C-based GFR was better compared to 
creatinine-based GFR in early detection of worsening clinical status. This 
suggests the utility of serum cystatin C over serum creatinine in predicting early 
decline in GFR and thereby helping in early therapeutic intervention. 
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3.  Study was conducted in the Department of internal medicine, Eulji 
University School of Medicine Seol, Korea, study done by Miyeon Chung, Dae 
Won Jun, and Su Ah Sung et al… 
The mean age of 53 cirrhotic patients was 59 years, with 38 males and 15 
female patients. Hepatitis B virus-related hepatitis was the most common cause 
of liver cirrhosis among the patients (39.6%), followed by alcoholic hepatitis 
(30.2%), hepatitis C virus-related hepatitis (5.7%), non-alcoholic steatohepatitis 
(5.7%), and unknown causes (18.9%). Ascites was found in 35 patients (66%). 
The average Child-Pugh score was 9.37±2.78, with Child-Pugh A consisting of 
8 patients (15.1%), Child-Pugh B of 19 patients (35.8%), and Child-Pugh C of 
26 patients (49.1%). The MELD score was 14.11±6.22, and the MELD-Na 
score was 16.41±7.48. The mean duration of follow-up was 13±8.9 months 
(average±standard deviation).  
Creatinine clearance and the e-GFRMDRD showed a negative correlation with 
serum cystatin C [r=-0.532 (p<0.001) and r=-0.691 (p<0.001), respectively], but 
had no correlation with urine cystatin C and urine cystatin C/urine creatinine 
ratio [r=-0.129 (p=0.2) and r=-0.124 (p=0.3), respectively]. Serum cystatin C 
showed a positive correlation with the MELD and MELD-Na scores [r=0.346 
(p=0.011) and r=0.427 (p=0.001), respectively] but had no correlation with the 
Child-Pugh score (r=0.234; p=0.09). Urine cystatin C was not correlated with 
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MELD score (p=0.108), MELD-Na score (p=0.123), or Child-Pugh score 
(p=0.5). 
Nine out of the 53 patients with liver cirrhosis developed acute kidney injury 
during the first three months of follow-up. The e-GFRMDRD did not yield 
noticeable differences between the groups with and without acute kidney injury 
(p=0.18), but the formulae utilizing serum cystatin C, i.e., e-GFRHoek and 
GFRLarsson, differed significantly between two groups (p=0.03 and p=0.03, 
respectively). 
To investigate the efficacy of serum creatinine and serum cystatin C in 
predicting acute kidney injury, the area under ROC curve was calculated. The 
results were 0.735 (95% CI, 0.525-0.945, p=0.028) for serum cystatin C and 
0.698 (95% CI, 0.495-0.901, p=0.063) in creatinine. Using the ROC curve, the 
appropriate cutoff values of serum cystatin C and creatinine for predicting acute 
kidney injury were 1.23 mg/L (sensitivity 0.667, 1-specificity 0.136) and 0.9 
mg/dl (0.85 mg/dl: sensitivity 0.778, 1-specificity 0.455; 0.95 mg/dl: sensitivity 
0.556, 1-specificity 0.273), respectively. The sensitivity, specificity, positive 
predictive value, and negative predictive value of the cystatin C reference value 
in regard to renal injury occurring within three months were found to be 66.7%, 
86.4%, 50%, and 92.7%, respectively. During the whole observation period, 17 
patients (32.1%) were developed acute kidney injury. The average initial serum 
creatinine and cystatin C levels were 1.00 mg/dl and 1.30 mg/L among patients 
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showing acute kidney injury. The area under the ROC curve was 0.809 (95% 
CI, 0.671-0.947, p<0.001) in serum cystatin C and 0.719 (95% CI, 0.568-
0.870, p=0.011) in creatinine. 
4.  Karina sofa, Silvia Coelho et all… Study was conducted patients admitted to 
the non surgical ED of the Fernando Fonseca Hospital from March to 
November 2008, Lisban Portugal. In this prospective cohort study, serum and 
urinary cystatin C were serially measured in a heterogeneous group of patients 
(n = 616) presenting to a tertiary care emergency department. The primary 
outcome was AKI, classified according to RIFLE and AKIN criteria. The 
secondary outcome was an adjudication based on clinical criteria to AKI, 
prerenal azotemia, chronic kidney disease (CKD), and normal kidney 
function.Results: Patients were adjudicated to have AKI in 21.1%, prerenal 
azotemia in 25.8%, CKD in 2.4%, and normal kidney function in 50.7%. For 
the diagnosis of AKI, the discriminatory ability of urinary creatinine and 
cystatin C was marginal. Both serum cystatin C and serum creatinine (at 
presentation and 6 hours later) showed high discriminatory ability for the 
diagnosis of AKI. However, only serum cystatin C attained a significant early 
predictive power (Hosmer-Lemeshow P value > 0.05). Serum cystatin C could 
differentiate between AKI and prerenal azotemia, but not between AKI and 
CKD.Conclusions: Serum cystatin C is an early, predictive biomarker of AKI, 
which outperforms serum creatinine in the heterogeneous emergency 
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department setting. However, neither biomarker discriminated between AKI and 
CKD. Additional biomarkers continue to be needed for improved specificity in 
the diagnosis of community-acquired AKI. 
MATERIALS AND METHODS 
This study was carried out in the  Department of General Medicine and 
Department of Medical Gastro Enterology at Government Stanley Medical 
College and Hospital,Chennai during the period  between  April 2017-
September 2017.This study was ethically approved by the Ethical Commitee of 
Government Stanley Medical College,Chennai 
 This study is a cross sectional study enrolling 50patient of DCLD with 
HRS.The patients were selected from  Department of General Medicine and 
Department of Medical Gastro enterology during the study period. 
INCLUSION CRITERIA 
• Patient age 18- 65 years  
• Decompensated liver diseases of all etiology. 
EXCLUSION CRITERIA 
• Known Renal Disease. 
• Known Renal Transplant. 
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• Immunocompromised state. 
• Past History of HRS. 
• Past History of Nephrotoxic Drugs. 
Applying all these criteria,50patient of DCLD with HRSwere selected and 
included in the study after taking their informed consent. 
METHODOLOGY 
Clinical sample and data  was collected from - 
1.Patients admitted in the Dept.of  General Medicine with DCLD & HRS, Govt. 
Stanley Hospital, Department of Medical Gastro Entrology.  
After screening, patients who fulfil inclusion criteria and showing willingness to 
participate in trial has been selected and included in study. A detailed history 
taking and clinical examination was done in all patients.  
• Investigations,  
1. CBC,  
2. RFT, RBS, electrolytes 
3. LFT, PT, INR 
4. Cystatin C 
5. Urine Analysis  
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6. Viral Markers (HBsAg, Anti HCV) 
7. Sr. Uric acid 
8. USG Abdomen 
9. ECG, X-ray chest 
10. OGD scopy  
Patients who has been selected for the study measured Cystatin C and Serum 
Creatinine Level compared by using cockroft gault formula. Results analysed 
and eGFR calculated by cockroft gault formula.    
1. Socio-demographic data :  
Age  
Sex 
Occupation / Income 
Family history 
Life Style  
Alcohol  
Smoking 
2. Clinical examination  
General Examination  
Systemic Examination  
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Abdomen :  Hepato Splenomegaly  
  Shifting dullness  
CVS :  S1S2 
Rs :  Pleural effusion  
CNS : Flaps  
Vital  
PR :  BP : 
 
STATISTICAL ANALYSIS 
Collected data was prepared into masterchart in Microsoft Excel and analysed 
statistically in SPSS software version 11.5.Results were considered if p value 
was below 0.05. 
The collected data were analysed with IBM.SPSS statistics software 23.0 
Version.To describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variables and the mean & S.D 
were used for continuous variables.To find the significance in categorical data 
Chi-Square test was used. In the above statistical tool the probability value .05 
is considered as significant level.  
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RESULTS 
1. AGE DISTRIBUTION  
 
 
 
• The mean age of the sample was 41.40 and the age ranged between a 28-
30 years with a standard deviation of 11.137 
 
 
 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
45.0
Upto 30 yrs 31 - 40 yrs 41 - 50 yrs 51 - 60 yrs
Age distribution
  Frequency Percent 
Valid Upto 30 yrs 3 6.0 
31 - 40 yrs 21 42.0 
41 - 50 yrs 21 42.0 
51 - 60 yrs 5 10.0 
Total 50 100.0 
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2) SEX 
Sex 
 
  Frequency Percent 
Valid Female 9 18.0 
Male 41 82.0 
Total 50 100.0 
 
In this study 82% were male patients and 18% female  
 
 
 
 
 
Gender
Female Male
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3. RISK FACTORS  
A) ALCOHOLISM  
Alcoholism 
  Frequency Percent 
Valid NO 14 28.0 
YES 36 72.0 
Total 50 100.0 
 
72% of the patients with DCLD were alcoholics  
 
 
 
 
Alcoholism
NO YES
48 
 
B)VIRAL HEPATITIS  
Hepatitis B 
  Frequency Percent 
Valid NO 41 82.0 
YES 9 18.0 
Total 50 100.0 
    Hepatitis C 
  Frequency Percent 
Valid NO 46 92.0 
YES 4 8.0 
Total 50 100.0 
 
 
18% of the patient with DCLD were Hepatitis B positive  
4% of the patient with DCLD were Hepatitis C Positive  
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
B C
Hepatitis
NO YES
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C)METABOLIC LIVER DISEASE  
Metabolic Liver disease 
  Frequency Percent 
Valid NO 46 92.0 
WILSONS 4 8.0 
Total 50 100.0 
 
4% of patients with DCLD were Wilsons Disease   
Metabolic Liver disease
NO WILSONS
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D)AUTO IMMUNE HEPATITIS  
Auto immune Hepatitis 
  Frequency Percent 
Valid NO 48 96.0 
YES 2 4.0 
Total 50 100.0 
 
 
2% of patients with DCLD were Auto immune Hepatitis  
 
 
 
 
Auto immune Hepatitis
NO YES
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4.COMPLICATIONS  
A) HRS  
HRS Type I 
  Frequency Percent 
Valid NO 13 26.0 
YES 37 74.0 
Total 50 100.0 
    HRS Type II 
  Frequency Percent 
Valid NO 37 74.0 
YES 13 26.0 
Total 50 100.0 
 
 Type I Type II 
NO 26.0 74.0 
YES 74.0 26.0 
 
Among 50 DCLD patients 74% were type I HRS, 26% were type II HRS  
Type I HRS more common than type II HRS  
0%
20%
40%
60%
80%
100%
Type I Type II
HRS
NO YES
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B) UGI Bleed  
UGI Bleed 
  Frequency Percent 
Valid NO 37 74.0 
YES 13 26.0 
Total 50 100.0 
 
 
 
 
Among 50 DCLD with HRS patients 26% were developed UGI Bleed.  
Type I HRS more common than type II HRS  
 
UGI Bleed
NO YES
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C) HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy 
  Frequency Percent 
Valid NO 37 74.0 
YES 13 26.0 
Total 50 100.0 
 
 
Among 50 DCLD patients 26% were developed Hepatic Encephalopathy  
 
 
 
 
Hepatic encephalopathy
NO YES
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D) COAGULOPATHY 
Coagulopathy 
  Frequency Percent 
Valid NO 41 82.0 
YES 9 18.0 
Total 50 100.0 
 
 
Among 50 DCLD patients 18% were developed Coagulopathy.  
 
 
 
 
Coagulopathy
NO YES
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E) SPONTANEOUS BACTERIAL PERITONITIS  
SBP 
  Frequency Percent 
Valid NO 43 86.0 
YES 7 14.0 
Total 50 100.0 
 
 
 
 
Among 50 DCLD patients 14% were developed Spontaneous Bacterial 
Peritonitis  
 
 
SBP
NO YES
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5.CHILD PUGH SCORE  
Child  Pugh score > 10 
 
Frequency Percent 
Valid NO 35 70.0 
YES 15 30.0 
Total 50 100.0 
 
 
In this study 30% of the patient having child pugh score >10 
 
 
 
 
 
 
Child  Pugh score > 10
NO YES
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Descriptive Statistics 
 
  N Minimum Maximum Mean 
Std. 
Deviation 
Age 50 28 60 41.40 7.253 
Cystatin C 50 .8 5.8 3.246 1.2209 
Serum 
Creatinine 
50 1.4 3.4 2.108 .5082 
GRF 50 51.1 86.1 70.862 9.6521 
Valid N 
(listwise) 
50         
 
Regression 
Variables Entered/Removeda 
Model 
Variables 
Entered Variables Removed Method 
1 Serum 
Creatinine, 
Cystatin Cb 
  Enter 
 
a. Dependent Variable: GRF 
 
b. All requested variables entered. 
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The derived regression equation is for the GRF is GRF = - 4.12* Cystatin C  - 
6.44 * Serum Creatnine + 97.83 and both were found to be highly statistical 
significant  influence with R square value 61.6 % with P = 0.01 < 0.05  
  
Model Summary 
  
Model R R Square 
Adjusted 
R Square 
Std. Error of the 
Estimate 
  1 .785a .616 .600 6.1076 
   
a. Predictors: (Constant), Serum Creatinine, Cystatin C 
 
   
 
      ANOVAa 
 
Model 
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regression 2811.812 2 1405.906 37.690 .000b 
Residual 1753.206 47 37.302     
Total 4565.018 49       
a. Dependent Variable: GRF 
b. Predictors: (Constant), Serum Creatinine, Cystatin C 
 
 
 
Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B 
Std. 
Error Beta 
Lower 
Bound 
Upper 
Bound 
1 (Constant) 97.835 3.721   26.295 .000 90.350 105.320 
Cystatin C -4.124 .936 -.522 -4.407 .000 -6.007 -2.242 
Serum 
Creatinine 
-6.444 2.248 -.339 -2.867 .006 -10.967 -1.922 
a. Dependent Variable: GRF 
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DISCUSSION 
DCLD is one of the major cause of mortality across the world. In India DCLD 
affects males more common than females. In India DCLD is leading gastro 
intestinal cause of mortality in males. In this study mainly concentrated 
advantage of cystatin C compared to creatinine and complication of DCLD. 
HRS (hepatorenal  syndrome) is one of the major complication that can leads to 
death of the patient. Because medical management does not helps to recover 
from HRS unless it is identified in a early stage.  
HRS is basically a diagnosis of exclusion. There is no biochemical substance 
available to diagnose HRS.  
Until now serum creatinine is the only renal parameter easily available & less 
cost parameter for diagnosing HRS. Serum creatinine is not a good markes for 
identify HRS at early stage.  
Serum creatinine is not a ideal parameter to diagnose HRS. Because Serum 
creatinine dependent on various other factors like age, muscle mass, sex, drugs, 
high bilirubin.  
It is essential to identify the HRS at early stage. Only parameter which is 
elevated before urea, creatinine is cystatin C. 
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Cystatin C raised in HRS at early stage before rising of renal parameters. 
Moreover Cystatin C  not dependent on age, sex, muscle mass etc.,  
In this study we found Cystatin C raised high levels eventhough serum creatine 
just above normal range. Study conducted at Government Stanley Medical 
College, Chennai over a period of 6 months to identify the advantage of 
Cystatin C over serum creatinine and commonest causes of DCLD, frequency of 
complications.  
Among 50 patient 9 (18%) females and 41 (82% ) males. DCLD more common 
in males.  
Risk factor (or) cause of DCLD, identified in this study were Alcohol (72%), 
Hepatitis B (18%), Hepatitis C (8%) metabolic liver disease (8%) Auto immune 
hepatitis (4%). Finally conclude Alcoholism is major cause for DCLD.  
Among 50 HRS patient HRS type I (74%) is more common than type II HRS 
(26%) 
We found HRS type II patient have developed other complications like Hepatic 
encephalopathy, UGI bleed, Coagulopathy, Spontaneous Bacterial peritonitis 
compared to HRS Type I.  
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USI bleed (26%), Hepatic encephalopathy (26%), Coagulopathy (18%), SBP 
(14%), Cystatin C highly elevated when GFR has minimally reduced, Serum 
Creatinine slowly rised when GFR reduced very low levels.    
Limitations of the study 
1. The sample size was small 
2. The study duration was small 
3. Our study did not have any data on mortality and recovery of the HRS 
patients. 
4. Our study we did not have any data on commonest cause for DCLD 
among female patient because female patient included in this study was 
very small. 
CONCLUSIONS 
1. Our study showed that Cystatin C is better biochemical parameter than 
serum creatinine for calculating eGFR. 
2. HRS type I more common than HRS type II 
3. HRS type II associated with other complications of DCLD like UGI 
bleed, Hepatic encephalopathy etc., 
4. Our study showed that Alcoholism is the most common cause for 
cirrhosis followed by viral hepatitis. 
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5. Whether the medical treatment improves the HRS not yet studied. This 
has to be assessed by future studies.  
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CASE REPORT FORM/PROFORMA 
NAME 
AGE 
SEX 
COMPLETE DIAGNOSIS  
TYPE OF HRS  
RISK FACTORS FOR DCLD  
DIAGNOSTIC INVESTIGATION 
CBC,  
RFT, RBS, electrolytes 
LFT, PT, INR 
Cystatin C 
Urine Analysis  
Viral Markers (HBsAg, Anti HCV) 
Sr. Uric acid 
USG Abdomen 
ECG, X-ray chest 
OGD scopy  
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Informed consent- ‘A study on parameters of Hepatorenal Dysfunction 
in Cases of DCLD at a Tertiary Care Centre’ 
Place of study:  Govt. Stanley medical college, Chennai 
I ……………………………………………. have been informed about the details of the study in my 
own language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I agree to collect samples of blood/saliva/urine/tissue if study needs. 
I understand that I can withdraw from the study at any point of time and even then, I can receive the 
medical treatment as usual. 
I understand that I will not get any money for taking part in the study. 
I will not object if the results of this study are getting published in any medical journal, provided my 
personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would extend my full 
cooperation for this study.   
  
 Volunteer:        Witness: 
Name and address        Name and address  
Signature/thumb impression:     Signature/thumb impression 
Date:        Date: 
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Informed consent- ‘A study on parameters of Hepatorenal Dysfunction 
in Cases of DCLD at a Tertiary Care Centre’ 
நான் இந்த ஆராய்ச்சி யி ல் வி வரங்களை முற்றி லும் புரி ந்து கொண்டேன்.  ஆய்வி ல் 
பங்கு எடுத்துபோது, சாத்தி யமான அபாயங்கள் மற்றும் பயன்களை பற்றி  நான் 
அறி ந்துள்ளேன். 
நான் எந்தவொ ரு வேளையி லும் ஆய்வி ல் இருந்து தி ரும்ப முடி யும், அதன் பி ன்னர், 
நான் வழக்கம் போல் மருத்துவ சி கி ச்சை பெற முடி யும் என்று புரி ந்து கொள்கி றேன். 
நான் ஆய்வி ல் பங்கு எடுத்து பணம் எதையும் பெற முடி யாது என்று அறி ந்துள்ளேன்.  
இந்த ஆய்வி ன் முடி வுகள் எந்த மெடி க்கல் ஜர்னலி ல் வெளி யி டப்பட இருந்தால் நான் 
எதி ர்க்கவி ல்லை, என் தனி ப்பட்ட அடையாளத்தை வெளி ப்படுத்தப்பட்டு இருக்ககூடாது. 
நான் இந்த ஆய்வி ல் பங்கெடுப்பதன் மூலம் நான் என்ன செய்யபோகி றேன் என்று 
தெரி யும். நான் இந்த ஆய்வி ல் என் முழு ஒத்துழைப்பையும் கொடுப்பேன் என்று 
உறுதி யளி க்கி றேன். 
 
தன்னா ர்வளர்       சாட்சி   
பெயர்மற்றும்முகவரி      பெயர்மற்றும்முகவரி  
கையொப்பம்  /வி ரல்ரேகை:     கையொப்பம் / வி ரல்ரேகை: 
 
 
ஆராய்ச்சி யாளராககையொப்பம்மற்றும்தேதி
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Sr.N
o. 
Ag
e Sex 
Alcoholi
sm 
Hepati
tis B 
Hepati
tis C 
Metabol
ic Liver 
disease 
Auto 
immu
ne 
Hepati
tis  
HRS 
Typ
e I 
HRS 
Type 
II 
Cystat
in C 
Serum 
Creatin
ine 
GR
F 
Child  
Pauc
k 
score 
>10 
UGI 
Bleed 
Hepatitic 
encephal
opathy  
Coagulop
athy SBP 
1 56 M YES NO NO NO NO YES NO 1.8 1.5 78.2 NO NO YES YES YES 
2 45 M YES NO NO NO NO YES NO 2.3 1.6 75.2 NO NO NO NO NO 
3 44 M YES NO NO NO NO YES NO 2.6 1.7 82.1 NO NO NO NO NO 
4 36 M YES NO NO NO NO NO YES 5.8 2.5 53.5 YES YES YES NO NO 
5 37 M YES NO NO NO NO YES NO 4.6 2.9 83.1 NO NO NO NO NO 
6 34 M YES NO NO NO NO YES NO 2.9 1.8 86.1 NO NO YES NO YES 
7 38 M NO YES NO NO NO YES NO 1.6 1.9 84.1 YES NO NO NO NO 
8 39 M NO NO YES NO NO YES NO 3.2 1.5 78.1 NO YES NO NO NO 
9 34 M YES NO NO NO NO YES NO 3.1 1.4 75.1 NO NO YES YES NO 
10 42 M YES NO NO NO NO YES NO 2.9 1.8 74.1 NO NO NO NO NO 
11 48 M YES NO NO NO NO NO YES 4.7 2.6 54.3 YES NO NO NO NO 
12 42 M YES NO NO NO NO NO YES 4.8 2.7 58.3 YES YES NO NO NO 
13 43 M NO YES YES NO NO NO YES 5.2 2.8 51.1 YES YES YES YES NO 
14 45 M NO NO NO NO NO YES NO 3.2 2 78.1 NO NO NO NO NO 
15 38 M YES NO NO NO NO YES NO 3.1 2.1 79.1 NO NO NO NO NO 
16 49 M YES NO NO 
WILSO
NS NO YES NO 2.9 1.8 80.2 NO NO NO NO NO 
17 56 M YES NO NO NO NO NO YES 4.8 2.5 57.9 YES YES YES NO NO 
18 54 M YES NO NO NO NO NO YES 4.1 2.4 56.3 YES YES NO NO NO 
19 60 M YES NO NO 
WILSO
NS NO NO YES 5 2.3 57.9 YES NO NO NO YES 
20 38 M YES NO NO NO NO YES NO 1.6 1.9 82.1 NO NO NO NO NO 
21 36 M YES NO NO NO NO YES NO 1.7 1.7 81.1 NO NO NO NO NO 
22 34 M YES NO NO NO NO YES NO 1.8 1.8 78.8 NO NO YES YES NO 
23 44 M YES NO NO NO NO YES NO 2.1 1.5 77.7 NO NO NO NO NO 
24 46 M YES NO NO NO NO YES NO 1.2 2.1 76.1 NO NO NO NO NO 
25 47 M NO YES NO NO NO YES NO 2.8 2.2 74.8 NO YES YES NO NO 
26 32 M NO YES NO NO NO YES NO 2.8 2.1 79.7 NO NO NO NO NO 
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27 29 M YES NO NO NO NO YES NO 3.2 2.3 72.1 YES NO NO NO YES 
28 30 M YES NO NO NO NO YES NO 3.3 1.9 74.1 NO NO NO YES NO 
29 28 M YES NO NO NO NO YES NO 3.5 2.8 69.1 NO NO NO NO NO 
30 40 M YES NO NO NO NO YES NO 3.6 1.8 70.1 NO NO NO NO NO 
31 42 M YES NO YES NO NO YES NO 2.9 1.6 71.2 NO NO NO NO NO 
32 44 M YES NO NO 
WILSO
NS NO YES NO 1.2 2.1 64.2 NO YES YES NO NO 
33 36 M YES NO NO NO NO YES NO 3.1 2.2 69.1 NO NO NO NO NO 
34 38 M NO YES NO NO NO YES NO 3.4 2.3 74.2 NO NO NO NO YES 
35 42 M YES NO NO NO NO YES NO 0.8 2.1 78.1 NO NO NO NO NO 
36 41 M YES NO NO NO NO YES NO 3.6 1.9 74.2 NO NO NO NO NO 
37 47 M YES NO NO NO NO NO YES 4.7 3.4 62.1 YES YES YES YES NO 
38 48 M YES NO NO NO NO NO YES 4.8 2.6 60.1 YES YES YES YES YES 
39 32 M YES NO NO NO NO NO YES 5.2 2.7 57.8 YES NO NO NO NO 
40 42 M YES NO NO NO NO YES NO 3.8 1.8 72.1 NO NO NO NO NO 
41 39 M YES YES NO NO NO YES NO 3 1.7 78.2 NO NO NO NO NO 
42 36 F YES NO NO NO NO YES NO 3.1 1.6 72.1 NO NO YES YES NO 
43 38 F NO YES NO NO NO YES NO 1.2 2.1 73.8 NO NO NO NO NO 
44 50 F NO YES NO NO NO YES NO 2.8 1.5 74.2 NO YES NO NO NO 
45 56 F NO NO YES NO NO YES NO 2.7 1.5 74.8 NO NO NO YES NO 
46 34 F NO NO NO NO YES YES NO 2.8 1.6 75.3 NO NO NO NO NO 
47 40 F YES YES NO NO NO YES NO 3.1 1.6 68.2 NO NO NO NO NO 
48 42 F NO NO NO NO NO NO YES 4.8 3.2 57.2 YES NO NO NO NO 
49 38 F NO NO NO 
WILSO
NS NO NO YES 4.1 3.1 54.5 YES YES YES NO YES 
50 41 F NO NO NO NO YES NO YES 5 2.9 53.2 YES YES NO NO NO 
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ABBREVIATIONS 
DCLD – Decompensated Liver Disease   
HRS-Hepato Renal Syndrome  
AKI-Acute Kidney Injury 
UGI-Upper Gastro Intestinal 
HE- Hepatic Encephalopathy  
MDRD-Modified Diet Renal Disease  
 eGFR-estimated glomerular filtration rate 
CysC-CystatinC  
GIT-gastrointestinal tract 
OGD-Oesophago Gastro Duodenoscopy  
 
